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to maintain the imperative of “primum, non nocere.” To
obtain evidence for future guidelines, plasma oxalate con-
centrations should be monitored in this kind of study to
see what happens when plasma ascorbate concentrations
double, or more, as they did in the above-mentioned study
after only eight weeks of supplementation.
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Reply from the Authors
I appreciate the comments by Dr. Canavese et al on
the optimal dose of vitamin C supplementation, and sub-
sequent risk of oxalosis in patients on chronic dialysis.
Plasma oxalate concentrations were examined in our pre-
vious study [1] for hemodialysis patients receiving vi-
tamin C supplementation of 300 mg postdialysis thrice
weekly for eight weeks. The vitamin C level significantly
increased after the first four weeks, and decreased slightly
during the second four-week period (Fig. 1A). In contrast,
plasma oxalate levels did not significantly increase after
eight weeks of intravenous vitamin C; although there was
a modest increase in oxalate level, it was marked only
for the first four weeks, and remained at a similar level
during the second four-week period (Fig. 1B). Thus, it is
speculated that there was no steady increase with time in
plasma oxalate levels in the present study using the same
dose frequency [2].
Hemodialysis patients are at risk for ascorbate defi-
ciency due to its dialytic loss, increased consumption, or
inadequate intake. Most studies documented lower than
normal plasma ascorbate concentrations in nonsupple-
mented hemodialysis patients [3, 4]. Therefore, a supple-
mentation of vitamin C is essential. Excessive vitamin
C treatment may worsen uremic-related oxalosis; how-
ever, supplementation not exceeding 150 mg daily is still
considered a safe dose [5]. Currently, in the case of sus-
pected subclinical ascorbate deficiency, 1 to 1.5 g of oral
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Fig. 1A. Changes of plasma ascorbate and oxalate concentrations in
hemodialysis patients not receiving (white bars, N = 15) and receiv-
ing intravenous vitamin C supplementation with response (black bars,
N = 18) or without (hatched bars, N = 19) during eight weeks of study.
(A) P < 0.05 versus patients not receiving vitamin C supplementation
at four weeks and eight weeks, respectively, and (B) P < 0.05 versus
baselines at week 0 in responders and nonresponders, respectively.
ascorbate weekly for hemodialysis patients, or 300 mg
of parenteral ascorbate three times weekly at the end
of dialysis, is recommended [6, 7]. Although there is no
long-term controlled study showing increasing oxalosis
risk in hemodialysis patients taking 1000 to 1500 mg/wk
of vitamin C, these doses can normalize plasma ascorbate
levels, and are considered safe for up to eight weeks with
respect to the danger of secondary oxalosis. I agree with
Dr. Canavese et al that long-term vitamin C replacement
studies are needed to monitor the oxalate levels, and to
determine the safety and efficacy in chronic kidney dis-
ease patients and those on maintenance dialysis therapy.
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Prospective study of
gentamicin locking of
tunnelled dialysis catheters:
The effect on infection rates
and CRP
To the Editor: Furthering the study recently published
from this unit on the utility of antibiotic-locking of tun-
nelled dialysis catheters [1], we report data obtained from
the unitwide adoption of this policy. Tunnelled catheters
are widely used for hemodialysis access, but their use is re-
stricted by catheter-related infection (CRI) [2]. Our orig-
inal randomized controlled study indicated that using a
combination of gentamicin and heparin for prophylactic
filling of new catheters was effective at reducing CRI [1].
All catheters in use at baseline were included, and had
been locked using 5000 IU/mL of heparin in saline only
for the preceding three months. After a two-month ob-
servation period, catheters were locked with gentamicin
(gentamicin 5 mg/mL, heparin 5000 IU/mL).
Forty-eight patients were included. Nine infections oc-
curred in eight patients in the observation period, five
in previously uninfected catheters. In comparison, 44 pa-
tients were studied in the two months following the intro-
duction of gentamicin locking. Two infections occurred
in two patients, none in previously uninfected catheters.
Overall, the rate of CRI dropped from 3.12/1000 catheter
days to 0.76/1000 catheter days (P < 0.05). CRP levels
were lower following the introduction of gentamicin lock-
ing (31.6 compared with 20.4 mg/L; P < 0.05). No organ-
isms were resistant to gentamicin.
These data are consistent with our original study, in
which CRI decreased from 4/1000 to 0.3/1000 catheter
days with gentamicin [1]. Levels of CRP dropped, indi-
cating an overall reduction in the inflammatory burden.
In a prevalent population of catheters, locking with
gentamicin is an effective means of reducing the rate of
CRI, and reduces CRP levels.
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Analgesic use in hemodialysis
patients: Osler at the bedside
and computer-generated data
To the Editor: We were disappointed in Dr. Baille’s
study design, analysis, and conclusion that analgesics are
underprescibed [1]. We investigated the use of intra-
venous analgesics in patients on hemodialysis [2], and
found that the most commonly used drugs were notorious
for serious problems. l−Agonists with active metabolites
that are renally excreted can cause unpredictable levels of
activity with life threatening complications. Dr. Baillie’s
report makes no distinction in types of narcotics, receptor
affinity, route of metabolism and excretion, the presence
of active metabolites, nor does he examine any analgesic
complications other than those for NSAIDs.
Similarly, since the authors make no distinction in the
various types of pain, they cannot distinguish patients
who were crippled from severe coronary artery disease
or diabetic patients with neuropathic pain. Yet while
the chest pain might be appropriately treated with ni-
trates, and the neuropathic pain might be well treated
with tricyclics, those patients would be considered un-
treated by the authors because they were not treated with
analgesics.
Finally, the suggestion that analgesics were underpre-
scribed is astounding. Dr. Baillie’s presumption that the
